shares of AngioDynamics, Inc. (NASDAQ: 
ANGO) are surging 5% in Tuesday's premarket session. The asset has broken the ceiling of a bullish rectangle pattern- couple with the RSI at 54, ANGO is set for a bullish spike amidst market sentiment.
Adding to the bullish thesis, AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
Report Highlights
Med Tech segment delivers fifth consecutive quarter of double-digit growth
Strong adjusted EBITDA; and positive cash flow
Three regulatory milestones support Mechanical Thrombectomy portfolio: Modified AlphaVac 510(k) clearance, PAVE and APEX-Return IDE approvals
Raised full year FY 2026 guidance for net sales and Adjusted EBITDA
Jim Clemmer to retire during fiscal year 2027 as President and CEO upon appointment of successor; Board initiates comprehensive CEO search.
Analyst Summary
According to 3 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $19.33, which is an increase of 46.11% from the latest price.
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium.
ANGO) are surging 5% in Tuesday's premarket session. The asset has broken the ceiling of a bullish rectangle pattern- couple with the RSI at 54, ANGO is set for a bullish spike amidst market sentiment.Adding to the bullish thesis, AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
Report Highlights
Med Tech segment delivers fifth consecutive quarter of double-digit growth
Strong adjusted EBITDA; and positive cash flow
Three regulatory milestones support Mechanical Thrombectomy portfolio: Modified AlphaVac 510(k) clearance, PAVE and APEX-Return IDE approvals
Raised full year FY 2026 guidance for net sales and Adjusted EBITDA
Jim Clemmer to retire during fiscal year 2027 as President and CEO upon appointment of successor; Board initiates comprehensive CEO search.
Analyst Summary
According to 3 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $19.33, which is an increase of 46.11% from the latest price.
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium.
Exención de responsabilidad
La información y las publicaciones no constituyen, ni deben considerarse como, asesoramiento o recomendaciones financieras, de inversión, de trading u otro tipo, proporcionadas o respaldadas por TradingView. Obtenga más información en Condiciones de uso.
Exención de responsabilidad
La información y las publicaciones no constituyen, ni deben considerarse como, asesoramiento o recomendaciones financieras, de inversión, de trading u otro tipo, proporcionadas o respaldadas por TradingView. Obtenga más información en Condiciones de uso.